Alaunos Therapeutics (TCRT) revenue and earnings history
Alaunos Therapeutics reported revenue of $5K for fiscal 2025 (year ended Dec 31, 2025), −50.0% on the year before, and net income of −$4.18M.
Over 14 years, from fiscal 2011 to fiscal 2025, revenue grew at a compound rate of −29.5% a year.
Revenue and net income, 22 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $5K−50.0% | −$4.22M | −$4.18M | −$2.87M | $98K | −$2.97M | $796K | — | — | $1.39M | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Alaunos Therapeutics (TCRT) on OQRO.
Common questions
What was Alaunos Therapeutics's revenue in fiscal 2025?
$5K for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 31, 2026. That is −50.0% on fiscal 2024 ($10K).
How fast has Alaunos Therapeutics's revenue grown?
From $667K in fiscal 2011 to $5K in fiscal 2025: a compound annual growth rate of −29.5% over 14 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Alaunos Therapeutics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
